BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 19259094)

  • 1. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
    Steele N; Finn P; Brown R; Plumb JA
    Br J Cancer; 2009 Mar; 100(5):758-63. PubMed ID: 19259094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
    Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
    Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
    Plumb JA; Strathdee G; Sludden J; Kaye SB; Brown R
    Cancer Res; 2000 Nov; 60(21):6039-44. PubMed ID: 11085525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP].
    Meng CF; Dai DQ; Guo KJ
    Ai Zheng; 2008 Dec; 27(12):1251-5. PubMed ID: 19079988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer.
    Kondo Y; Shen L; Issa JP
    Mol Cell Biol; 2003 Jan; 23(1):206-15. PubMed ID: 12482974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer.
    Strathdee G; MacKean MJ; Illand M; Brown R
    Oncogene; 1999 Apr; 18(14):2335-41. PubMed ID: 10327053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells.
    Shaker S; Bernstein M; Momparler LF; Momparler RL
    Leuk Res; 2003 May; 27(5):437-44. PubMed ID: 12620295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
    Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
    Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reassembly of nucleosomes at the MLH1 promoter initiates resilencing following decitabine exposure.
    Hesson LB; Patil V; Sloane MA; Nunez AC; Liu J; Pimanda JE; Ward RL
    PLoS Genet; 2013; 9(7):e1003636. PubMed ID: 23935509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer.
    Cameron EE; Bachman KE; Myöhänen S; Herman JG; Baylin SB
    Nat Genet; 1999 Jan; 21(1):103-7. PubMed ID: 9916800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic approaches to cancer therapy.
    Plumb JA; Steele N; Finn PW; Brown R
    Biochem Soc Trans; 2004 Dec; 32(Pt 6):1095-7. PubMed ID: 15506976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.
    Glasspool RM; Brown R; Gore ME; Rustin GJ; McNeish IA; Wilson RH; Pledge S; Paul J; Mackean M; Hall GD; Gabra H; Halford SE; Walker J; Appleton K; Ullah R; Kaye S;
    Br J Cancer; 2014 Apr; 110(8):1923-9. PubMed ID: 24642620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA demethylation is superior to histone acetylation for reactivating cancer-associated genes in ovarian cancer cells.
    Meng CF; Su B; Li W
    Mol Med Rep; 2011; 4(6):1273-8. PubMed ID: 21850374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.
    Fang F; Munck J; Tang J; Taverna P; Wang Y; Miller DF; Pilrose J; Choy G; Azab M; Pawelczak KS; VanderVere-Carozza P; Wagner M; Lyons J; Matei D; Turchi JJ; Nephew KP
    Clin Cancer Res; 2014 Dec; 20(24):6504-16. PubMed ID: 25316809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
    Luszczek W; Cheriyath V; Mekhail TM; Borden EC
    Mol Cancer Ther; 2010 Aug; 9(8):2309-21. PubMed ID: 20682643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re-expression of methylation-induced tumor suppressor gene silencing is associated with the state of histone modification in gastric cancer cell lines.
    Meng CF; Zhu XJ; Peng G; Dai DQ
    World J Gastroenterol; 2007 Dec; 13(46):6166-71. PubMed ID: 18069755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer.
    Balch C; Yan P; Craft T; Young S; Skalnik DG; Huang TH; Nephew KP
    Mol Cancer Ther; 2005 Oct; 4(10):1505-14. PubMed ID: 16227399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
    Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
    Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic regulation of the KAI1 metastasis suppressor gene in human prostate cancer cell lines.
    Sekita N; Suzuki H; Ichikawa T; Kito H; Akakura K; Igarashi T; Nakayama T; Watanabe M; Shiraishi T; Toyota M; Yoshie O; Ito H
    Jpn J Cancer Res; 2001 Sep; 92(9):947-51. PubMed ID: 11572762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor.
    Gray SG; Baird AM; O'Kelly F; Nikolaidis G; Almgren M; Meunier A; Dockry E; Hollywood D; Ekström TJ; Perry AS; O'Byrne KJ
    Int J Mol Med; 2012 Dec; 30(6):1505-11. PubMed ID: 23007409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.